The company's Synapse DBS system offers implantable therapies for movement disorders, and has been deployed in clinical studies for the treatment of urological disorders. Nuviant Medical arose from viable clinical programs developed internally and acquired from Medtronic, and has produced and tested its device conforming to Good Manufacturing Practice (GMP) in its class 10,000 clean-room. Its founder, Will Rosellini, initiated these programs at Rosellini Scientific via support from the National Institutes of Health (NIH) SBIR program.